Off-label studies on apremilast in dermatology: a review

Abstract Purpose: Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. Materials and methods: The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term ‘apremilast,’ with results manually screened to identify published data on off-label uses of apremilast. The article was structured by the quality of evidence available. Results: Apremilast use in dermatology beyond plaque psoriasis and psoriatic arthritis is frequently described in the literature, with a mixture of positive and negative results. Randomized controlled data is available for Behçet’s disease, hidradenitis suppurativa, nail/scalp/palmoplantar psoriasis, alopecia areata, and atopic dermatitis. Conclusion: The relatively safe adverse effect profile of apremilast and its broad immunomodulatory characteristics may make it a promising option in the future for patients with difficult to treat diseases in dermatology, refractory to first line therapies, but further studies will be necessary to clarify its role.

[1]  E. Simpson,et al.  A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis. , 2019, The Journal of investigative dermatology.

[2]  F. Bérard,et al.  Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment , 2018, The British journal of dermatology.

[3]  M. Furue,et al.  Three cases of palmoplantar pustulosis successfully treated with apremilast , 2018, The Journal of dermatology.

[4]  A. Vossen,et al.  Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial , 2019, Journal of the American Academy of Dermatology.

[5]  C. Chiaverini,et al.  Treatment of Severe Hailey-Hailey Disease With Apremilast , 2018, JAMA dermatology.

[6]  M. Lebwohl,et al.  A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata , 2018, Archives of Dermatological Research.

[7]  T. Honda,et al.  A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast. , 2018, Acta dermato-venereologica.

[8]  L. French,et al.  Successful treatment of SAPHO syndrome with apremilast , 2018, The British journal of dermatology.

[9]  S. Zheng,et al.  Apremilast Ameliorates Experimental Arthritis via Suppression of Th1 and Th17 Cells and Enhancement of CD4+Foxp3+ Regulatory T Cells Differentiation , 2018, Front. Immunol..

[10]  L. Bielory,et al.  Chronic tearing induced by apremilast. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  J. Sánchez-Carazo,et al.  Complex Aphthae Treated With Apremilast. , 2018, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[12]  M. Komine,et al.  A case of anti-laminin γ1 (p200) pemphigoid with psoriasis vulgaris successfully treated with apremilast , 2018, European Journal of Dermatology.

[13]  Jean-Paul J. Abboud,et al.  Apremilast Use in a Case of Cicatricial Ectropion Secondary to Severe Lamellar Ichthyosis. , 2018, Ophthalmic plastic and reconstructive surgery.

[14]  L. Pescitelli,et al.  Cutaneous hyperpigmentation induced by apremilast , 2018, International journal of dermatology.

[15]  M. Gooderham,et al.  Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[16]  M. Lebwohl,et al.  Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL. , 2018, Journal of drugs in dermatology : JDD.

[17]  Á. González-Cantero,et al.  Successful Treatment of Refractory Type 1 Pityriasis Rubra Pilaris With Apremilast , 2018, Journal of cutaneous medicine and surgery.

[18]  M. D’Incan,et al.  A case of severe pityriasis rubra pilaris with a dramatic response to apremilast , 2018, European Journal of Dermatology.

[19]  D. Rigopoulos,et al.  Rapid clearance of erythrodermic psoriasis with apremilast. , 2017, Journal of dermatological case reports.

[20]  L. Gottwald,et al.  Repigmentation of Tenacious Vitiligo on Apremilast , 2017, Case reports in dermatological medicine.

[21]  N. Maloney,et al.  Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation , 2017, Dermatologic therapy.

[22]  Kelli King-Morris,et al.  Proximal Renal Tubular Acidosis (Fanconi Syndrome) Induced by Apremilast: A Case Report. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  B. Kaffenberger,et al.  Purpura Annularis Telangiectodes of Majocchi Associated With the Initiation and Rechallenge of Apremilast for Psoriasis Vulgaris. , 2017, JAMA dermatology.

[24]  W. Liao,et al.  Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities , 2017, JAAD case reports.

[25]  B. King,et al.  Lack of efficacy of apremilast in 9 patients with severe alopecia areata , 2017, Journal of the American Academy of Dermatology.

[26]  N. Yawalkar,et al.  Apremilast for treatment of recalcitrant aphthous stomatitis , 2017, JAAD case reports.

[27]  K. Peris,et al.  Long‐term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) , 2017, Journal of the American Academy of Dermatology.

[28]  B. Strober,et al.  Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. , 2017, Journal of drugs in dermatology : JDD.

[29]  M. Lebwohl,et al.  Apremilast for Lichen Planopilaris and Frontal Fibrosing Alopecia: A Case Series , 2017 .

[30]  N. Yawalkar,et al.  Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients , 2017, Journal of the American Academy of Dermatology.

[31]  M. Kalavala,et al.  Successful treatment of refractory palmoplantar pustulosis with apremilast , 2017, Clinical and experimental dermatology.

[32]  J. Yeung,et al.  Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report , 2017, Journal of cutaneous medicine and surgery.

[33]  D. West,et al.  Apremilast and suicidality – a retrospective analysis of three large databases: the FAERS, EudraVigilance and a large single‐centre US patient population , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[34]  S. Meehan,et al.  Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum , 2017, JAAD case reports.

[35]  J. Levitt,et al.  Apremilast for treatment of recurrent erythema multiforme. , 2017, Dermatology online journal.

[36]  N. Shear,et al.  Treatment of recalcitrant erosive oral lichen planus and desquamative gingivitis with oral apremilast. , 2017, Journal of dermatological case reports.

[37]  J. Lacour,et al.  Appearance of lentigines in psoriasis patients treated with apremilast. , 2016, Journal of the American Academy of Dermatology.

[38]  J. Gooderham.  Treatment of Palmoplantar Pustulosis with the Combination of Ustekinumab and Apremilast: A Case Report , 2016 .

[39]  L. French,et al.  Apremilast Is Effective in Lichen Planus Mucosae-Associated Stenotic Esophagitis , 2016, Case Reports in Dermatology.

[40]  M. Bettencourt.  Oral Lichen Planus Treated With Apremilast. , 2016, Journal of drugs in dermatology : JDD.

[41]  N. Jaipaul,et al.  Erythrodermic Psoriasis Treated with Apremilast , 2016, Dermatology reports.

[42]  K. Hasegawa,et al.  Levonorgestrel-releasing intrauterine system placement for severe uterine cervical stenosis after conization: two case reports , 2016, Journal of Medical Case Reports.

[43]  C. Curiel-Lewandrowski,et al.  Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast. , 2016, JAMA dermatology.

[44]  M. Gooderham,et al.  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). , 2016, Journal of the American Academy of Dermatology.

[45]  M. Genovese,et al.  Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study , 2015, Arthritis & rheumatology.

[46]  P. Merkel,et al.  Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study. , 2015, The New England journal of medicine.

[47]  B. Chakraborty,et al.  An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study. , 2014, JAMA dermatology.

[48]  D. Pariser,et al.  An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series. , 2013, Journal of the American Academy of Dermatology.

[49]  B. Strober,et al.  Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. , 2012, Journal of drugs in dermatology : JDD.

[50]  E. Simpson,et al.  A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. , 2012, Archives of dermatology.

[51]  A. Gottlieb,et al.  A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. , 2012, Journal of drugs in dermatology : JDD.

[52]  R. Baughman,et al.  Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. , 2012, Archives of dermatology.

[53]  G. Schett,et al.  Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases , 2010, Therapeutic advances in musculoskeletal disease.

[54]  Lei Wu,et al.  Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis , 2010, British Journal of Pharmacology.